Werewolf Therapeutics, Inc. (HOWL)
NASDAQ: HOWL · Real-Time Price · USD
1.360
+0.030 (2.26%)
At close: Jan 21, 2025, 4:00 PM
1.420
+0.060 (4.41%)
After-hours: Jan 21, 2025, 7:48 PM EST
Werewolf Therapeutics Employees
Werewolf Therapeutics had 47 employees as of December 31, 2023. The number of employees increased by 1 or 2.17% compared to the previous year.
Employees
47
Change (1Y)
1
Growth (1Y)
2.17%
Revenue / Employee
$72,043
Profits / Employee
-$1,321,660
Market Cap
60.61M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 47 | 1 | 2.17% |
Dec 31, 2022 | 46 | 7 | 17.95% |
Dec 31, 2021 | 39 | 15 | 62.50% |
Dec 31, 2020 | 24 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
HOWL News
- 8 days ago - Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook - GlobeNewsWire
- 2 months ago - Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference - GlobeNewsWire
- 2 months ago - Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting - GlobeNewsWire
- 3 months ago - Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting - GlobeNewsWire
- 5 months ago - Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 7 months ago - Werewolf Therapeutics: Continuing To Advance And Show More Promise In Phase 1 - Seeking Alpha
- 7 months ago - Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma - GlobeNewsWire
- 8 months ago - Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors - GlobeNewsWire